The Challenges of Validating AI Solutions in Life Science Companies

The Challenges of Validating AI Solutions in Life Science Companies

Artificial intelligence (AI) is transforming the life sciences industry—from accelerating drug discovery to optimizing clinical trial operations. But as AI adoption grows, so does the complexity of validating these solutions. For life science companies, especially those operating in regulated environments, validating AI is not just a technical hurdle—it’s a regulatory, ethical, and operational challenge.

In a panel discussion at a recent AI-focused life science conference, a question was posed on validation models.  One speaker, whose role focuses on clinical trial development, expressed that his organization considers validation in relation to meeting clinical requirements. A second speaker, a former FDA  regulatory official, explained that the FDA  focuses their efforts on examining the underlying data used to train and validate the model.

Why AI Validation Matters

In life sciences, validation ensures that a system consistently performs as intended. For traditional software, this process is well-defined. But AI, especially machine learning (ML) models, introduces variability. These systems learn from data and evolve over time, making them less predictable and harder to validate using conventional methods.

In clinical trials, where patient safety and data integrity are paramount, the stakes are even higher. An unvalidated AI tool could lead to biased patient selection, flawed data analysis, or regulatory non-compliance.

Key Challenges in AI Validation

 1. Dynamic and Non-Deterministic Behavior

Unlike static software, AI models can change their behavior based on new data. This makes it difficult to lock down a single version of the system for validation. Even small changes in input data can lead to different outputs, which complicates reproducibility and traceability—two core principles of validation.

 2. Lack of Regulatory Clarity

Regulatory bodies like the FDA and EMA are still evolving their guidance on AI and ML in clinical settings. While frameworks like the FDA’s “Good Machine Learning Practice” (GMLP) provide a starting point, there is no universal standard for validating AI in life sciences. This uncertainty makes it hard for companies to know what’s “good enough” for compliance.

 3. Data Quality and Bias

AI is only as good as the data it’s trained on. In clinical trials, data can be messy, incomplete, or biased. If an AI model is trained on non-representative data, it may produce skewed results—potentially excluding certain patient populations or misinterpreting outcomes. Validating the model requires not just testing its performance, but also auditing the data pipeline for quality and fairness.

 4. Explainability and Transparency

Many AI models, especially deep learning systems, operate as “black boxes.” They can make highly accurate predictions, but it’s often unclear how they arrived at those conclusions. In a regulated environment, this lack of explainability is a major barrier. Regulators, clinicians, and patients all need to understand how decisions are made—especially when those decisions impact trial design or patient care.

 5. Integration with Legacy Systems

Life science companies often rely on a patchwork of legacy systems for data capture, trial management, and reporting. Integrating AI into these environments can be technically challenging. Validation must account for how the AI interacts with existing systems, ensuring that it doesn’t introduce errors or inconsistencies.

 6. Change Management and Version Control

AI models may need to be retrained or updated as new data becomes available. Each update can affect performance, requiring re-validation. Managing these changes—tracking versions, documenting updates, and ensuring continuity—is a complex task that requires robust governance.

 

Best Practices for AI Validation

Despite the challenges, several best practices can help life science companies validate AI more effectively:

  • Define Intended Use Clearly: Start with a clear definition of what the AI system is supposed to do. This helps scope the validation effort and align it with regulatory expectations.
  • Use a Risk-Based Approach: Focus validation efforts on areas where AI decisions have the greatest impact on patient safety or data integrity.
  • Document Everything: Maintain detailed records of model development, training data, testing protocols, and performance metrics.
  • Ensure Human Oversight: AI should support—not replace—human decision-making. Include mechanisms for human review and override.
  • Plan for Continuous Validation: Treat AI validation as an ongoing process, not a one-time event. Monitor performance over time and revalidate as needed.

Summary

AI holds enormous promise for improving clinical trial efficiency, accuracy, and scalability. But realizing that promise requires rigorous validation. Life science companies must navigate a complex landscape of evolving regulations, technical uncertainty, and ethical considerations. By adopting a structured, risk-based approach to AI validation, organizations can harness the power of AI while maintaining trust, compliance, and scientific integrity.